Trials / Recruiting
RecruitingNCT06213974
A Study of Maribavir in Adults and Children With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
Post Authorization Study to Monitor Efficacy, Effectiveness, and Safety of Maribavir (LIVTENCITY®) in Patients With Post-transplant Cytomegalovirus (CMV) Infection in Argentina
- Status
- Recruiting
- Phase
- —
- Study type
- Observational
- Enrollment
- 10 (estimated)
- Sponsor
- Takeda · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The main aim of this study is to learn about the safety of Maribavir in adults and children with post-transplant CMV infection in routine clinical practice in Argentina. The other aim is to study the effectiveness of the treatment with Maribavir in routine clinical practice in Argentina. Participants will be treated by their doctors according to normal medical practice. Study data will be collected either from information already available in the medical records or during study conduct.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | No Intervention | This is non-interventional study. |
Timeline
- Start date
- 2024-09-03
- Primary completion
- 2026-06-01
- Completion
- 2026-09-01
- First posted
- 2024-01-19
- Last updated
- 2025-07-09
Locations
1 site across 1 country: Argentina
Source: ClinicalTrials.gov record NCT06213974. Inclusion in this directory is not an endorsement.